Cathie's Ark Logo
Caredx Inc Logo

Combined Holdings of CareDx (CDNA) - Updated Daily

GenomicsGenetic Testing

Key Statistics

⚖️Weighting🧢Market Cap
🏋️‍♀️Weight Rank Across All Funds🌏Country
41🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$37.80 - ARKG
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos

Other ETFs That Hold CDNA

ARKGARK Genomic Revolution ETF3.5%
GNOMGlobal X Genomics & Biotechnology ETF0.92%
XBISPDR® S&P Biotech ETF0.61%
LABUS&P Biotech Bull 3X Shares ETF0.102%
IBBiShares Biotechnology ETF0.06%

Research Notes and Commentary for CDNA

No Research Notes Found for CDNA